Aldeyra Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have filed a Schedule 13G, reporting beneficial ownership of 6.22% of Aldeyra Therapeutics, Inc. common stock as of June 30, 2026.
NASDAQ
The Vanguard Group reports 0% beneficial ownership in Aldeyra Therapeutics Inc. following an internal realignment.
NASDAQ
Perceptive Advisors and its affiliates reported a beneficial ownership of 8.7% in Aldeyra Therapeutics, Inc., holding 5,222,311 common shares.
NASDAQ
Perceptive Advisors and its affiliates have increased their beneficial ownership in Aldeyra Therapeutics, Inc. to 6.8% of common stock.
NASDAQ
SCHEDULE 13G/A: Perceptive Advisors Discloses 8.2% Stake in Aldeyra Therapeutics
Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has disclosed a beneficial ownership of 8.2% in Aldeyra Therapeutics, Inc., totaling 4,875,851 common shares.